Bristol-Myers Squibb Announces Dividend Increase

NEW YORK--(BUSINESS WIRE)-- The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a 3% percent increase in the company’s quarterly dividend, beginning in the first quarter of 2012.

The dividend increase will result in a quarterly dividend of thirty-four cents ($0.34) per share on the $.10 par value Common Stock of the corporation for an indicative 2012 full-year dividend of $1.36 per share, subject to the normal quarterly review by the Board. The next quarterly dividend will be payable on February 1, 2012, to stockholders of record at the close of business on January 6, 2012.

The Directors also declared a quarterly dividend of fifty cents ($0.50) per share on the $2.00 Convertible Preferred Stock of the corporation, payable March 1, 2012, to stockholders of record at the close of business on February 3, 2012.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.



CONTACT:

Bristol-Myers Squibb
Media:
Jennifer Fron Mauer, 609-252-6579
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Mylan recalls one lot of the injectable antibiotic daptomycin after discovering particles in a single-dose vial.

AbbVie's Allergan received a positive early ruling in its long-running trade secrets dispute with Evolus over a competitor to blockbuster Botox.

As Amgen ramps up clinical trials of its psoriasis drug Otezla in COVID-19, it might also be studying its blockbuster Enbrel in fighting the virus.